- Sitryx to participate in upcoming April investor conferences
- MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
- Mushrooms Inc. (OTC: MSRM) Achieves Proof of Concept for MycoLabX Infection-Detection Technology and Provides Strategic Update
- Scientists and explorers unite at the Yacht Club de Monaco for 'A Day of Exploration'
- Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Checkerspot Announces Breakthrough, using Microalgae to Produce Palmitoleic Acid Oil at Scale, Opening a New Pathway to Omega-7s
- China SXT Pharmaceuticals, Inc. Announces Share Re-classification
- Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
- Groundbreaking Danish research project launches to cure Parkinson’s disease
